KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) EBITDA Margin (2018 - 2025)

Castle Biosciences (CSTL) has disclosed EBITDA Margin for 8 consecutive years, with 4.4% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 909.0% to 4.4% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 12.44% through Dec 2025, down 1505.0% year-over-year, with the annual reading at 12.44% for FY2025, 1505.0% down from the prior year.
  • EBITDA Margin hit 4.4% in Q4 2025 for Castle Biosciences, up from 8.19% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 5.92% in Q3 2024 to a low of 91.7% in Q1 2022.
  • Historically, EBITDA Margin has averaged 26.46% across 5 years, with a median of 17.22% in 2023.
  • Biggest five-year swings in EBITDA Margin: plummeted -7294bps in 2022 and later skyrocketed 6749bps in 2024.
  • Year by year, EBITDA Margin stood at 25.68% in 2021, then plummeted by -132bps to 59.55% in 2022, then skyrocketed by 86bps to 8.56% in 2023, then surged by 155bps to 4.69% in 2024, then crashed by -194bps to 4.4% in 2025.
  • Business Quant data shows EBITDA Margin for CSTL at 4.4% in Q4 2025, 8.19% in Q3 2025, and 4.93% in Q2 2025.